ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|
 
Print Page
Email Article

First trial of gene therapy for serious pain very successful, moves quickly to phase 2 at U of Michigan

  [ 15 votes ]   [ Post a Comment ]
www.ProHealth.com • April 19, 2011

previous article next article

This gene, delivered via injected viral DNA, is taken up by the nervous system & produces a natural opioid in the target pain pathway.

In the first clinical trial of gene therapy for treatment of intractable pain, researchers at the University of Michigan Department of Neurology observed that the treatment appears to provide substantial pain relief.

In a study published online by the Annals of Neurology, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.

NP2 is a gene transfer vector that expresses the opioid peptide enkephalin (naturally released by neurons in the central nervous system & adrenal gland).

In preclinical work in animals, a team led by Dr. David Fink, MD, chair of the Department of Neurology, had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation, or cancer.

In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain.

"The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Dr. Fink.

"In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80% reduction in pain over the course of 4 weeks following treatment."

Product of 20 Years’ Research

Dr. Fink's laboratory has been working on the use of modified Herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years.

Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the US subsidiary of Diamyd Medical.

The recombinant replication defective HSV approach represents a platform technology – a nerve targeting drug delivery system (NTDDS) - that can be used to deliver and express any one of a number of genes in the nervous system.

A related NTDDS vector, NG2 reduces pain-related behaviors in preclinical models of neuropathic pain from nerve injury and diabetes.

NTDDS gene transfer to the DRG to express neurotrophins locally prevents the progression of polyneuropathy in relevant preclinical models, suggesting that the NTDDS platform may be used to treat degenerative polyneuropathies as well.

"This is an example of translational research in which we have moved from laboratory bench studies through animal models into new treatment that we are testing patients. There was no placebo control in this phase 1 study, but the apparent dose-dependent pain relief was encouraging to us," Dr. Fink says.

A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.
___

Source: University of Michigan Health System news release, Apr 11, 2011 


previous article
  Rating 4.4 (15 votes) next article




DISCUSS THIS ARTICLE   (0 existing comments) Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Your Next Order

Featured Products
Vitamin D3 5000 IU Vitamin D3 5000 IU
Give your body a boost with the sunshine vitamin
Natural Resveratrol Natural Resveratrol
Powerful Antioxidant Support + Positive Anti-aging Effects
Omega 3-6-9 Omega 3-6-9
All three EFAs in one convenient form
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
OsteoTec™ UC-II® OsteoTec™ UC-II®
A True Breakthrough in Joint health

Most Viewed Articles
What's the Hidden Cause Behind YOUR Fibromyalgia Flares? [more]

VIDEO: IACFS/ME Conference - Summary of Research by Dr. Komaroff [more]

How to Limit or Minimize Your Fibromyalgia Flare [more]

Mitochondrial Dysfunction, Post-Exertional Malaise and CFS/ME [more]

The Devil Is In The Details – A Herpes Simplex Virus Inquiry For Fibromyalgia and Chronic Fatigue Sy... [more]

Review of Nutritional Supplements Used for ME/CFS and FM [more]

Sympathetic Nervous System Dysfunction in FIbromyalgia and Overlapping Conditions [more]

FREE: Stop Feeding Yourself PAIN Guide [more]

Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel sy... [more]

EBV I: A Deficient Immune Response, Increased Levels of Epstein-Barr Virus Opens Up EBV Question in ... [more]


FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing